Loading...

World-Class Retina Care. Community-Based Caring.

Dr. Abbey Delivered On-Demand Presentation About the PHOTON DME Study for ASRS 2025 Meeting

Posted On August 6, 2025 / By / Posted in Blog

Dr. Abbey Delivered On-Demand Presentation About the PHOTON DME Study for ASRS 2025 Meeting

On behalf of the PHOTON study investigators, Texas Retina’s Ashkan M. Abbey, MD, delivered an on-demand presentation titled “Differential Anatomic Response to Aflibercept 8 mg vs 2 mg During Matched Dosing Phase

read more
Posted On July 25, 2025 / By / Posted in Blog

Texas Retina Research Team Members Attended Ollin Study Meeting in Maui

This past weekend, seven members of Texas Retina’s research team were invited to attend the Ollin Study Coordinators meeting in Maui, Hawaii. Ollin is a Phase Ib study of two different formulations

read more
Posted On June 24, 2025 / By / Posted in Blog

Dr. Abbey Presented Study Results of Two Investigational Wet AMD Treatments at Clinical Trials Summit

This past weekend, Texas Retina’s Director of Clinical Research for Dallas Ashkan M. Abbey, MD, led two presentations at the annual Clinical Trials at the Summit (CTS) meeting in Las Vegas, which

read more
Posted On June 16, 2025 / By / Posted in Blog

Initial Results of Phase Ib LOTUS Clinical Trial on Potential New Diabetic Macular Edema Treatment Released

On June 9, 2025, Eluminex Biosciences Limited, a clinical-stage protein therapeutics company, announced positive topline safety, tolerability, and pharmacodynamic data from the multicenter LOTUS Part 1 clinical trial of EB-105 in patients

read more
Posted On June 5, 2025 / By / Posted in Blog

Dr. Abbey Discusses How Vorolanib Could Shift the Treatment Approach for Diabetic Macular Edema in New Retinal Physician Article

Texas Retina’s Ashkan M. Abbey, MD, served as a principal site investigator for the Phase II VERONA clinical trial evaluating the efficacy and safety of the vorolanib intravitreal insert (EYP-1901) in diabetic

read more
Posted On April 29, 2025 / By / Posted in Blog

Dr. Abbey Shares 36-Month Results of Pegcetacoplan Treatment for Geographic Atrophy in AMD

On behalf of the investigators for the OAKS, DERBY, and GALE clinical trials, Texas Retina’s Director of Clinical Research for Dallas, Ashkan Abbey, MD, co-authored an article titled, “Pegcetacoplan Treatment for Geographic

read more
Posted On March 19, 2025 / By / Posted in Blog

Texas Retina Clinical Research Coordinator Rachel McCullough Participates in Panel Discussion for LUGANO and LUCIA Clinical Trials

At a recent meeting in San Antonio, Texas Retina Clinical Research Coordinator Rachel McCullough participated in a panel discussion with study coordinators for EyePoint Pharmaceuticals’ pivotal Phase III LUGANO and LUCIA clinical

read more
Posted On February 21, 2025 / By / Posted in Blog

Dr. Abbey Serves as Guest Editor for Latest Issue of Retina Today

Texas Retina’s Ashkan M. Abbey, MD, served as guest medical editor for the January/February 2025 issue of Retina Today along with Christina Y. Weng, MD, from Baylor College of Medicine. Retina Today

read more
Posted On February 12, 2025 / By / Posted in Blog

Dr. Abbey Discusses Injectable Retina Treatments on AAO Podcast

On a recent episode of the American Academy of Ophthalmology’s “Experts InSight” podcast, Texas Retina’s Ashkan Abbey, MD, joined Ehsan Rahimy, MD, and host Jay Shridhar, MD, to discuss recent developments in

read more
Posted On February 4, 2025 / By / Posted in Blog

Texas Retina Research Team Publishes New Study on Wet AMD Treatment

Texas Retina’s Ashkan Abbey, MD; Paige Abril, BS; and Rachel McCullough, BS, recently published a retrospective study in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina titled, “Outcomes of Intravitreal Aflibercept

read more